Information Provided By: 
Fly News Breaks for November 16, 2015
BXLT, DYAX, SHPG
Nov 16, 2015 | 16:18 EDT
As reported previously, Leerink analyst Jason Gerberry upgraded Shire to Outperform from Market Perform, citing the recent pullback in the pharma sector, positive OPUS-3 study results, the acquisition of Dyax (DYAX), its strong orphan and ophthalmology businesses and assurances that it will only structure a potential deal with Baxalta (BXLT) in the best interest of Shire shareholders. Gerberry raised his lifitegrast and HAE franchise estimates and increased his price target on Shire shares to $239 from $220.
News For SHPG;DYAX;BXLT From the Last 2 Days
There are no results for your query SHPG;DYAX;BXLT
